Company Description
Tempus AI, Inc. operates as a healthcare technology company in the United States.
It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.
Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.
It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, and Recursion Pharmaceuticals, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.
Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 14, 2024 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 2,400 |
| CEO | Eric Lefkofsky |
Contact Details
Address: 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 United States | |
| Phone | 800 976 5448 |
| Website | tempus.com |
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $37.00 |
| CIK Code | 1717115 |
| CUSIP Number | 88023B103 |
| ISIN Number | US88023B1035 |
| Employer ID | 47-4903308 |
| SIC Code | 7370 |
Key Executives
| Name | Position |
|---|---|
| Eric P. Lefkofsky J.D. | Co-Founder, Chief Executive Officer, President and Chairman |
| Ryan Fukushima | Chief Operating Officer |
| Andrew Polovin | Executive Vice President, General Counsel and Secretary |
| James Rogers | Chief Financial Officer |
| Ryan M. Bartolucci CPA | Chief Accounting Officer |
| Shane Colley | Chief Technology Officer |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
| Erik Phelps | Executive Vice President, Assistant Secretary and Chief Administrative and Legal Officer |
| Elizabeth Krutoholow | Vice President of Investor Relations and Competitive Intelligence |
| Patty Spiller | Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 19, 2026 | 144 | Filing |
| Feb 19, 2026 | 144 | Filing |
| Feb 19, 2026 | 144 | Filing |
| Feb 19, 2026 | 144 | Filing |
| Feb 19, 2026 | 144 | Filing |